Mylan (MYL) incorrectly' classified EpiPens - CNBC, citing regulators

September 28, 2016 2:38 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Mylan (NASDAQ: MYL) 'incorrectly' classified EpiPens, according to CNBC, citing regulators.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Litigation, Trader Talk

Add Your Comment